Skip to main content
. 2020 Dec 10;10:21762. doi: 10.1038/s41598-020-78646-y

Figure 6.

Figure 6

Combination treatment with lapatinib and ipatasertib enhances antiproliferative activity in PIK3CA-mutant HER2+ breast cancer cell lines. (a) Antiproliferative activity of combination treatment with fulvestrant and lapatinib, and triple-combination treatment with fulvestrant, lapatinib, and ipatasertib in PIK3CA-wild-type and PIK3CA-mutant HER2+ breast cancer cell lines. Three PIK3CA-wild-type (BT474, SK-BR-3, and ZR-75-30; left) and three PIK3CA-mutant (UACC893, HCC1954, and MDA-MB-361; right) HER2+ breast cancer cell lines were used. Cells were treated with fulvestrant and lapatinib (blue), or triple-combination treatment with fulvestrant, lapatinib, and ipatasertib (red) for 8 days (mean ± SD [n = 3]). The Y-axis indicates the relative ATP amounts (%). The relative ATP amounts were calculated using chemiluminescence assay and compared with the chemiluminescence of the DMSO control on day 8. (b) Quantified data of ipatasertib combination effects form Fig. 6a. The effects of ipatasertib were calculated using the following formula: ipatasertib combination effects = (%ATP with triple-combination treatment with fulvestrant, lapatinib, and ipatasertib)—(%ATP with fulvestrant and lapatinib treatment). Statistical analyses were performed using the non-parametric Wilcoxon–Mann–Whitney test. Differences were considered significant at p < 0.05. F, Fulvestrant; L, Lapatinib; I, Ipatasertib.